Clinical Trials Browser

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Hormone Receptor Positive Breast Carcinoma

Breast Neoplasms, Hyperglycemia

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Neoplasm Metastasis

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal, Breast

Squamous Cell Carcinoma of Head and Neck

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Lymphangioma

Colorectal Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Head and Neck Squamous Cell Cancer

Breast Neoplasms

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck

Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

Neoplasm Metastasis, Rectal Neoplasms

Breast Neoplasms, Ovarian Neoplasms, Recurrence

Breast Neoplasms

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Clinical Trials

TARGET-VM

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

GERTRUDE

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

ASSET

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

SAFIR 03

METALLICA

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

ALTREM

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

SMMART Adaptive Clinical Treatment (ACT) Trial

Compassionate Use of BYL 719 Alpelisib

ALCAP

ROME

TAILOR

SAFIR-PI3K

PIKNIC

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma